← brief for 2026-08-13 · Slowing decline
Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist.
Key takeaways
A study of orforglipron use in patients with type 2 diabetes. It found no difference in cardiovascular or renal outcomes.
Who did this work
Ramadurgum P · Shah J · Shah E · Palmer BF
Source
Article · PubMed, the drug frontier · 2026 Jul 28
https://pubmed.ncbi.nlm.nih.gov/42582425/